CompletedNot Applicable

The Clinical Study of Botulinum Toxin Type A Injection in the Treatment of Wilson Disease

China60 participantsStarted 2016-12-01

Plain-language summary

In order to expand the treatment of Wilson disease and improve the quality of life of patients with Wilson's disease, the clinical effect of botulinum toxin type A injection on Wilson's disease was discussed.

Who can participate

Age range15 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria：1.Conform to the diagnosis of "2012 European Liver Study Guidelines for Diagnosis and Treatment of hepatolenticular degeneration". 2. Aged from 15 to 65 years. Exclusion Criteria:Non-Wilson's disease

What they're measuring

Unified Dystonia Rating Scale(UDRS)

Timeframe: 4 weeks

Unified Wilson's Disease Rating Scale(UWDRS)

Timeframe: 4 weeks

Numeric Rating Scales(NRS)

Timeframe: 4 weeks

Activity of Daily Living Scale(ADL)

Timeframe: 4 weeks

Trial details

NCT IDNCT06762509

SponsorThe First Affiliated Hospital of Anhui University of Traditional Chinese Medicine

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-12-01

View on ClinicalTrials.gov More Wilson Disease trials